Skip to main content

Table 1 Parturient demographics and baseline characteristics of the phenylephrine, norepinephrine and control group

From: Effects of continuous infusion of phenylephrine vs. norepinephrine on parturients and fetuses under LiDCOrapid monitoring: a randomized, double-blind, placebo-controlled study

Variables Control group (n = 78) Phenylephrine group (n = 71) Norepinephrine group (n = 74) F value P value
Age, years 34.04 (4.80) 33.34 (3.77) 33.70 (4.26) 0.4904 0.6130
Weight, kg 77.77 (12.28) 75.36 (8.43) 76.09 (11.41) 0.9642 0.3829
Height, cm 162.41 (5.72) 161.70 4.27 (4.27) 161.77 (5.46) 0.4253 0.6541
BMI, kg/m2 29.49 (4.52) 28.79 (2.59) 29.06 (3.92) 0.6635 0.5161
Baseline CO, L/min 8.42 (2.46) 7.87 (2.58) 8.43 (2.53) 1.182 0.3087
Baseline SVR, dyn s m2/ cm5 968.37 (344.23) 968.37 (269.26) 971.17 (340.18) 0.045 0.9561
Baseline SV, ml 95.83 (25.14) 91.26 (26.87) 93.85 (24.46) 0.6079 0.5454
Baseline SBP, mmHg 120.19 (11.72) 117.14 (9.66) 120.64 (12.38) 2.054 0.1306
Baseline DBP, mmHg 68.44 (13.04) 66.49 (9.79) 69.54 (11.98) 1.245 0.2901
Baseline MAP, mmHg 81.28 (15.81) 78.68 (11.31) 81.59 (18.59) 0.7657 0.4662
Baseline Heart rate, beats/min 87.38 (12.81) 87.41 (11.57) 91.16 (10.54) 2.797 0.0631
  1. BMI Body Mass Index, Data are expressed as mean (SD); SD Standard deviation. *0.25 μg/kg/min phenylephrine vs. control group, P < 0.05; #0.05 μg/kg/min norepinephrine vs. control group, P < 0.05; †0.25 μg/kg/min phenylephrine vs. 0.05 μg/kg/min norepinephrine group, P < 0.05 based on ANOVA